What is the appropriate method to test for high-risk human papillomavirus (HPV) in a 76-year-old woman?

HPV Testing in a 76-Year-Old Woman

Routine cervical cancer screening, including HPV testing, should have been discontinued at age 65 years if this woman had adequate prior negative screening results. At age 76, she is well beyond the recommended screening cessation age, and initiating or continuing routine screening is not indicated unless she has specific symptoms or a history of high-grade lesions 1, 2.

Key Considerations for This Age Group

When Screening Should Stop

According to current guidelines, women older than 65 years should discontinue cervical cancer screening if they have had adequate prior screening with negative results 1, 2. "Adequate screening" is defined as:

• Negative HPV tests or co-testing (HPV plus cytology) at ages 60 and 65 years (preferred), OR
• Three consecutive negative cytology tests at recommended intervals with the last test at age 65 3

Important caveat: The 2026 American Cancer Society update now specifically recommends HPV testing at ages 60 and 65 years as a prerequisite for safely exiting screening, in response to high rates of cervical cancer among individuals older than 65 years with poor implementation of prior exit criteria 3.

Exceptions Requiring Continued Screening

Continue screening beyond age 65 in women with:

• History of CIN 2, CIN 3, or cervical cancer (continue for at least 25 years after treatment) 4
• Inadequate prior screening history (less than 3 consecutive negative tests in the past 10 years) 1, 5
• Current immunosuppression 3
• Abnormal screening results within the past 5 years 1

If Testing Is Indicated

When HPV Testing Should Be Performed

If this 76-year-old woman has inadequate prior screening or falls into an exception category, high-risk HPV testing is the most effective screening method for elderly women 5, 6.

Testing Methods

High-risk HPV DNA testing can be performed by:

1. Clinician-collected cervical specimen (preferred method) 7, 3

   • Collected during pelvic examination
   • Can be combined with cytology (co-testing)
   • Most validated approach

2. Self-collected vaginal specimen (acceptable alternative) 3

   • FDA-approved device/assay combinations only
   • Requires 3-year screening interval (vs. 5 years for clinician-collected)
   • Useful for overcoming access barriers

Specific Testing Recommendations

• Test only for high-risk (oncogenic) HPV types 8
• Do NOT test for low-risk HPV types - they provide no clinical benefit 7
• Prefer assays that differentiate HPV 16/18 from other high-risk types 9, 10
  • HPV 16 and 18 carry highest cancer risk in elderly women 8, 6
  • Extended typing for HPV 16/18/31/33/45/52/58 shows superior predictive value for CIN2+ in elderly women 6

Evidence Supporting HPV Testing in Elderly Women

Recent research demonstrates that HPV testing is significantly more predictive than cytology alone in women over 65 years:

• HPV-positive test increases CIN 2+ risk 136-fold compared to HPV-negative 5
• Abnormal cytology increases risk only 13-fold 5
• Extended HPV typing (16/18/31/33/45/52/58) has higher Youden index (0.41) than cytology (0.29) or high-risk HPV without typing (0.07) 6

Clinical Algorithm

For a 76-year-old woman:

1. First, determine if screening is appropriate:

   • Review screening history from ages 55-65
   • If adequate negative screening → No testing indicated
   • If inadequate screening, immunosuppressed, or history of high-grade lesions → Proceed to step 2

2. If testing is indicated:

   • Perform high-risk HPV DNA test (preferred over cytology alone)
   • Use assay that identifies HPV 16/18 specifically
   • Clinician-collected cervical specimen preferred

3. Interpret results:

   • HPV negative: Can discontinue screening if this represents adequate screening
   • HPV positive for types 16/18: Immediate colposcopy 4
   • HPV positive for other high-risk types: Reflex cytology, then manage based on cytology result 4

Critical Pitfalls to Avoid

• Do not perform routine screening in women >65 with adequate prior negative results - this leads to unnecessary procedures and potential harm 2
• Do not use low-risk HPV testing - it has no clinical utility 7, 8
• Do not assume all elderly women should stop screening - inadequate prior screening (present in 70% of women in one study) necessitates continued surveillance 5
• Do not use cytology alone if HPV testing is available - HPV testing is far more sensitive for detecting high-grade lesions in this age group 5, 6